Plus Therapeutics Aktie

Plus Therapeutics presented clinical and translational data from the phase‑1 ReSPECT‑LM study of REYOBIQ at a scientific conference. Patients treated with the dose recommended for phase‑2 showed a median overall survival of about 9 months versus historical 2–6 months, along with a reduction in circulating tumor cells and signs of clinical benefit. Translational analyses suggest immune modulation in the tumor microenvironment, and the multiple‑dose study is ongoing; the development is supported by grant funding. Despite the positive data, the company — with a market capitalization of around $41 million — remains under financial pressure, and analyst price targets range from $12 to $65. » More on de.investing.com

Plus Therapeutics unanimously appointed Ronald A. Andrews to its board of directors to fill the vacancy created by the resignation of Dr. Robert Lenk. Andrews was also named to the nominations and corporate governance committee and is regarded as an independent director; he is to stand for re-election at the 2026 annual general meeting. Andrews brings more than 35 years of experience in diagnostics and molecular diagnostics. » More on de.investing.com

Plus Therapeutics completed a type B meeting with the FDA on REYOBIQ for the treatment of leptomeningeal metastases; the focus was on the design of a registration‑enabling trial. The company plans to adapt its LM study according to the FDA’s recommendations, expects to provide an update after receiving the meeting minutes in early 2026, and thereby accelerates the development plan. Financials show high cash burn; a recent capital raise brought in about USD 13 million, and Plus obtained a 180‑day NASDAQ extension; the LM program is supported by a USD 17.6 million grant. » More on de.investing.com